title: Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?
abstract: BACKGROUND
  Infiltrating lobular carcinomas (ILC) represent approximately 10% of all breast cancers. The literature is mixed regarding their prognosis when compared with infiltrating duct carcinomas (IDC). There are few data regarding the treatment of ILC with radiation therapy.
  
  
  METHODS
  The clinical, pathologic, laboratory, and survival data of 161 patients with ILC were compared with the data of 1138 patients with IDC.
  
  
  RESULTS
  ILCs were larger, more difficult to excise completely, and more difficult to diagnose clinically. All prognostic factors measured were more favorable for ILC. Nodal positivity for ILC was 32%, compared with 37% for IDC (P = 0.22). The 7-year disease-free Kaplan-Meier survival (DFS) was 74% for patients with ILC and 63% for patients with IDC (P < 0.03). The 7-year breast cancer specific survival (BCSS) was 83% for patients with ILC and 77% for patients with IDC (P < 0.04). Selected patients with smaller lesions were treated with excision and radiation therapy. Patients with ILC treated with radiation therapy had a better DFS and BCSS than did patients with IDC treated with radiation therapy.
  
  
  CONCLUSIONS
  ILCs often are homogeneous, small cell tumors of low nuclear grade. Their desmoplastic reaction may be absent or less marked than that of IDC, making them more difficult to palpate and to visualize mammographically. Despite this, they can be treated successfully with either mastectomy or excision and radiation therapy.
authors.affiliation: Breast Center, Van Nuys, CA 91405.
authors.forename: M J
authors.initials: MJ
authors.lastname: Silverstein
authors.forename: B S
authors.initials: BS
authors.lastname: Lewinsky
authors.forename: J R
authors.initials: JR
authors.lastname: Waisman
authors.forename: E D
authors.initials: ED
authors.lastname: Gierson
authors.forename: W J
authors.initials: WJ
authors.lastname: Colburn
authors.forename: G M
authors.initials: GM
authors.lastname: Senofsky
authors.forename: P
authors.initials: P
authors.lastname: Gamagami
mesh_terms: D000367:Age Factors; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D001918:Brachytherapy; D001943:Breast Neoplasms / Q000473:pathology* / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology* / Q000628:therapy*; D018275:Carcinoma, Lobular / Q000473:pathology* / Q000628:therapy*; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008408:Mastectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011882:Radiotherapy, High-Energy; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents